WBSI Guided Personalized Delivery of TTFields
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with "standard array mapping" (based on regular contrast enhanced MRI) or an "alternative (more precise) array mapping" based on sophisticated state of the art MRI techniques including "whole brain spectroscopy". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 22 lata
- •Potwierdzony rozpoznaniem glejaka wielopostaciowego
- •Przebyta operacja usunięcia nowotworu oraz radioterapia
- •Prawidłowe funkcjonowanie wątroby, nerek i krwinek
- •Zgoda na leczenie elektroterapią (Optune)
✗ Disqualifies
- •Glejak w dolnej części mózgu (poniżej móżdżku)
- •Ciąża
- •Aktywny implant medyczny w mózgu (stymulator, rozrusznik serca, drenaż)
- •Alergia na żele przewodzące elektryczność (jak żel do EKG)
- •Znaczące krwawienie w okolicy nowotworu
Simplified criteria — AI translation
Trial details
- Minimum age
- 22 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Abramson Cancer Center
Philadelphia, United States
Penn Medicine, University of Pennsylvania
Philadelphia, United States
Trial contact
Demetrius Lee
Neuroradiology Research Core
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.